Patients with RET fusion-positive PTCs were significantly younger than patients with BRAF V600E and RAS-mutated carcinomas (P < 0.001) and had significantly larger tumor than patients with the BRAF V600E-mutated carcinomas (P < 0.001). The gene discussed is BRAF; the disease is neoplasm.